Diisopropyl 3,3-dimethoxycyclobutane-1,1-dicarboxylate

We are Diisopropyl 3,3-dimethoxycyclobutane-1,1-dicarboxylate CAS:115118-68-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:Diisopropyl 3,3-dimethoxycyclobutane-1,1-dicarboxylate
CAS.NO:115118-68-8
Synonyms:3,3-di(isopropoxycarbonyl)-1,1-dimethoxycyclobutane
Molecular Formula:C14H24O6
Molecular Weight:288.33700
 
Specification:
Appearance:Yellowish transparent liquid
Purity:≥98.0%
Moisture:≤0.2%
Other single purity:≤1.0%
 
Pack:200 kg/barrel, can also be packaged according to customer requirements
Synthesis:Synthesis of 1,3-Dibromo-2,2-dimethoxypropane and Diisopropyl malonate
Application:Synthesis of 3-oxocyclobutane-1-carboxylic acid intermediates

Diisopropyl 3,3-dimethoxycyclobutane-1,1-dicarboxylate


Related News: Remogliflozin is economical than other similar agents currently available in sodium glucose co-transporter-2 (SGLT2) inhibitors class, which shall help for its better access among middle and low socio-economic strata of the society, he added.2-(Chloromethyl)-3,4-dimethoxypyridine Hydrochloride The Company’s first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line.N- (m-tolil) dibenzo [b, d] furan-4-amina CAS:1609080-03-6 Capacity: the bottleneck of business growth, expanding capacity and increasing utilization become a trend. Capacity is the core factor that determines the supply capacity of API companies. Insufficient capacity will cause companies to selectively complete orders and produce varieties, limiting the expansion of API products and market development.3-chloro-2-(trifluoromethyl)aniline CAS:432-21-3 This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine.This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.

Related Products
Product Name
FMOC-S-trityl-L-cysteine View Details
5-Fluoro-2-oxindole View Details
3-trifluoromethylbenzoic acid View Details
2-Chloro-5-chloromethylpyridine manufacturer 2-Fluoro-5-iodo-4-methylpyridine manufacturer 4-chloro-7-methoxyquinoline-6-carboxamide manufacturer 2-Amino-4-chloro-6-methoxypyrimidine manufacturer D-Aspartic Acid manufacturer